TrialMedical oncology (Northwood, London, England)2018

Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.

Koji Nishimoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.